Steve Reed, CEO of HDT Bio. (HDT Bio Photo)
Seattle-based biotech company HDT Bio closed a seed round totaling roughly $3 million to support work on its COVID-19 vaccine candidate HDT-301.
Researchers from HDT Bio and the University of Washington in July published a rapid-release paper in the